Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s share price traded up 3.1% during trading on Wednesday . The company traded as high as $4.25 and last traded at $4.32, 1,605 shares changed hands during mid-day trading. A decline of 98% from the average session volume of 85,262 shares. The stock had previously closed at $4.19.

CRVS has been the topic of a number of recent analyst reports. Roth Capital assumed coverage on Corvus Pharmaceuticals in a research report on Wednesday, May 29th. They set a “buy” rating and a $6.00 price target on the stock. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $7.25.

The company’s 50-day moving average is $3.89 and its 200 day moving average is $4.18. The company has a debt-to-equity ratio of 0.03, a current ratio of 9.17 and a quick ratio of 9.17.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, August 1st. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.02). As a group, research analysts anticipate that Corvus Pharmaceuticals Inc will post -1.59 earnings per share for the current fiscal year.

In related news, major shareholder Holdings A/S Novo sold 1,400,000 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $4.00, for a total value of $5,600,000.00. Following the sale, the insider now owns 4,380,800 shares in the company, valued at $17,523,200. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Orbimed Advisors Llc purchased 657,344 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was acquired at an average price of $3.72 per share, for a total transaction of $2,445,319.68. The disclosure for this purchase can be found here. Insiders have bought 840,766 shares of company stock valued at $3,083,912 over the last quarter. Insiders own 40.40% of the company’s stock.

A number of hedge funds have recently made changes to their positions in CRVS. Parametric Portfolio Associates LLC purchased a new stake in Corvus Pharmaceuticals during the second quarter worth $50,000. Paloma Partners Management Co acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at $149,000. Millennium Management LLC increased its holdings in Corvus Pharmaceuticals by 61.2% in the 4th quarter. Millennium Management LLC now owns 60,248 shares of the company’s stock worth $221,000 after acquiring an additional 22,878 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Corvus Pharmaceuticals during the second quarter worth $223,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Corvus Pharmaceuticals by 18.3% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 58,951 shares of the company’s stock valued at $237,000 after purchasing an additional 9,101 shares in the last quarter. Institutional investors own 82.83% of the company’s stock.

About Corvus Pharmaceuticals (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Featured Article: What is a put option?

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.